Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of AZD5634 on Mucociliary Clearance in Cystic Fibrosis
NCT02950805Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of azd5634 in cystic fibrosis (CF) (2 arms), sponsored by AstraZeneca. Primary endpoint: Percentage of average whole lung particle clearance between 0 and 60 minutes. Started May 2017; status: completed.
02
Drugs
azd5634
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02950805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950805.